Gene expression in oestrogen-dependent human breast cancer xenograft tumours. by Thompson, A. M. et al.
Br. J. Cancer (1990), 62, 78-84
C Macmillan
Gene expression in oestrogen-dependent human breast cancer xenograft
tumours
A.M. Thompson'"2, C.M. Steel2, M.E. Foster2, D. Kerr3, D. Paterson4, D. Deane2,
R.A. Hawkins', D.C. Carter' & H.J. Evans2
'Department ofSurgery, Royal Infirmary ofEdinburgh, Lauriston Place, Edinburgh EH3 9YW; 2MRC Human Genetics Unit,
Western General Hospital, Crewe Road, Edinburgh EH4 2XU; 3Beatson Institute, Garscube Estate, Switchback Road, Glasgow
G61 IBD; and4Department ofPathology, University ofEdinburgh, Teviot Place, Edinburgh EHI ILS, UK.
Summary Xenograft tumours from an oestrogen-dependent human breast cancer cell line MCF-7 have been
established and characterised in thymectomised, irradiated female CBA strain mice. There was evidence for
selection in xenografts of a subpopulation of MCF-7 cells with an altered pattern of gene expression as
measured by mRNA levels compared with the original cells in vitro. Tumorigenicity increased significantly on
repeated animal passage but oestrogen dependence was retained. Following injection of the mice with
oestrogen, mitosis was induced in the tumour cells with associated increases in thymidine uptake and
percentage of cells in S-phase. In accord with these changes, c-myc and p53 expression were increased and
TGF-beta was suppressed. Thereafter the expression of the c-myc and p53 genes fell whilst that of the
TGF-beta gene was induced-as the oestrogenic stimulus declined. The oestrogen-regulated mRNA pS2 showed
a biphasic response to oestrogen and levels declined as the serum oestrogen fell to undetectable levels. This
xenograft system demonstrates that changes in transcription of oncogenes, growth factor and oestrogen-
regulated genes can be detected in vivo in response to oestrogen. It thus provides an in vivo model for studies
of the biochemical and molecular basis for therapeutic manipulation of hormone-sensitive human breast
cancer.
In studying the molecular biology of cancer cells, the
significance of in vitro observations may be uncertain due to
the absence of host factors that influence tumour behaviour
in vivo. Recent work on experimental human breast tumours
in vivo has made use, almost exclusively, of congenitally
athymic ('nude') mice (Osborne et al., 1988; Brunner et al.,
1989). We have previously reported the growth of a range of
human tumours in thymectomised, irradiated mice (Busuttil
et al., 1986) which have advantages in ease of husbandry and
cost (Steel et al., 1978; Morten et al., 1984; Hay et al., 1985).
We report here the characterization of an oestrogen-
responsive tumour derived from the MCF-7 human breast
carcinoma cell line grown in vivo in female thymectomised
and irradiated CBA mice. In addition, we have examined the
kinetics of the expression of a range of related genes (c-myc,
p53, TGF-beta and pS2) following oestrogenic stimulation in
this tumour model system.
Materials and methods
Twenty-one day old female mice from an established
breeding colony of CBA/Ca strain mice at the Institute of
Animal Technology, Western General Hospital, Edinburgh,
maintained as described in Hay et al. (1985), were anaes-
thetised with ether and suction thymectomy performed.
Three weeks after thymectomy, 200mgkg'I arabinoside C
(Pfizer, UK) was injected by the intraperitoneal route and
48 h later the mice were irradiated to a total body dose of
7.50 Gy. Radiation was delivered from an X-ray source
(250 kv: 0.3-0.4 Gy min-') with a Thoreus II filter. MCF-7
cells (Soule et al., 1973) were cultured in Nunclon flasks
(Nunc, Kamstrup, Denmark), fed regularly with Dulbecco's
Modified Eagle Medium (DMEM; Gibco, Paisley, UK) con-
taining phenol red (which has an oestrogenic effect on MCF-
7 cells) supplemented with 12% fetal calf serum (FCS;
Gibco) and maintained in an atmosphere containing 5% CO2
at 37°C. All cultures were persistently negative for myco-
plasma using conventional immunofluorescence techniques
(Goding, 1983). The cells were harvested in the logarithmic
(subconfluent) phase of growth and washed twice in
phosphate-buffered saline (PBS). A single dose of I0' viable
cells suspended in 50-100 pl PBS was injected into the fourth
right mammary fat pad 1-3 weeks after irradiation. At this
time 50 ftg oestradiol benzoate (Intervet UK Ltd., Cam-
bridge, UK) in 50fl arachis oil was injected subcutaneously
into the nape of the neck. This injection of 50 ftg oestradiol
benzoate in arachis oil was repeated every three weeks to the
same site. MCF-7 cells were also injected into 20 CBA mice
without oestrogen supplementation. A further 20 mice were
tested with a second regime: either a 1.25 mg or a 0.5 mg
oestradiol 6-week-release pellet (Innovative Research, Ohio,
USA) was placed subcutaneously. Tumours were measured
daily in two dimensions by the same author using calipers.
The volume of the tumour was calculated using the formula
pi/12 x (mean diameter)3.
Mice were killed at selected times and the tumours were
frozen immediately in liquid nitrogen or fixed for histology.
Those mice which did not develop tumours were killed 90
days from the start of the experiment. Mice which died in the
interim were examined in detail for evidence of disease.
Fragments of xenograft material arising from inocula of
MCF-7 cells were further transplanted through a dorsal
incision into additional thymectomised, irradiated mice under
anaesthetic. An injection of 50 pg 17 beta oestradiol benzoate
in arachis oil was administered as the mouse awoke.
Thereafter the transplant-bearing mice were treated as above.
Remaining tumour fragments were macerated and added to
DMEM containing 12% FCS and the tumour cells returned
to culture for 8 weeks before reinjection into mice or extrac-
tion of total ribonucleic acid (RNA).
Two additional human breast cancer cell lines MDA-MB-
231 (Cailleau et al., 1974) and T47-D (Keydar et al., 1979)
were cultured and similarly maintained. The cells were
harvested in the logarithmic phase of growth so that the
RNA could be extracted for comparison with that from the
MCF-7 cells.
Serum oestradiol concentration
Serum was prepared from individual samples of blood
(0.3-0.8 ml) taken by cardiac puncture from each of 30 mice
at specified times following the 3-weekly oestradiol benzoate
injections. The concentration of 17P-oestradiol was deter-
mined in 50ftl samples of serum using a commercially
available radioimmunoassay (Baxter Health Care, Newbury,
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Berks., UK). Within assay CV was 5% and between assay
CV was 6%.
Cellular DNA synthesis
Percentage of cells in 'S' phase. A monoclonal antibody,
BR9, directed against the halogenated nucleotide 5-
bromodeoxyuridine (5BrdU) was raised by one of the
authors (D.D.) and used for rapid S-phase measurements
(Gonochoroff et al., 1985).
A total of 200tl of 6 mgmll 5-BrdU (Sigma) was
injected into the peritoneal cavity of each mouse under
examination at 0, 6, 12, 18, 24, 36, or 48 h after injection of
50jig 17,-oestradiol. Each mouse was killed 1 h after
administration of the BrdU and the cells were released from
the tumours by dispase digestion and fixed in 70% ethanol.
A double staining procedure was used for the differentiation
of human MCF-7 cells from invading host (mouse) cells.
Fixed cells were incubated with 10fig of an antihuman class I
monoclonal antibody PE25 (D.D.), washed in PBS and 2tig of phycoerythrin-labelled anti-mouse conjugate added
(Southern Biotechnology Associates Inc.). To prevent cross-
reactivity of this antibody with the BR9, the cells were then
incubated in PBS containing 10 ig ml-' mouse IgG (Sigma)
for 30 min. After a wash in PBS, 10 ig of the monoclonal
antibody BR9 was added to the pellet of 106 cells and
incubated at room temperature for 40 minutes, washed in
PBS and incubated for a further 40 minutes in the presence
of 2 tg fluoroscein isothiocyanate (FITC)-labelled goat anti-
mouse conjugate (Sigma). After a final wash in PBS the cells
were analysed on a FACScan flow cytometer (Becton Dick-
son, Lincoln Park, NJ, USA) for the absolute number of
cells and the proportion of tumour cells in S phase.
Thymidine incorporation Thymidine uptake was also used as
an index of DNA synthesis in the isolated tumour cells. For
each time point, intact cells were separated from the dispase/
DMEM digests by density centrifugation over 5-30% Ficoll
400 gradient (Pharmacia, Uppsala, Sweden) and 150,l ofcell
suspension (106 cells ml-' DMEM with 5% added FCS) were
added per well of a 96-well mitcrotitre plate (Falcon 3072,
Becton Dickson). One 11Ci 3H-thymidine (Amersham Interna-
tional, Aylesbury, UK) was added to each well and the cells
were harvested 5 h later on to glass fibre discs. The radio-
activity emitted from each disc was counted in 5 ml of scintil-
lant (Opti-Scint, Pharmacia, Sweden) in a Packard 1600CA
analyser (Packard, Downers Grove, Illinois, USA).
Histopathology
A slice through the middle of each tumour was fixed in
methacarn for 1 h then 95% ethanol and then processed
routinely. Paraffin sections were cut and examined after
staining with haematoxylin and eosin. The mitotic index for
each tumour was calculated from the mean number of
mitoses in 50 randomly chosen, high-power fields (x 400) by
one author (D.P.).
Oestrogen receptor concentration
The soluble oestrogen receptor concentration of xenograft
tissue or cells was measured following homogenisation by a
standard method (Hawkins et al., 1981) and use of the
Enzyme Immuno-Assay (EIA; Kit from Abbott
Laboratories, North Chicago, Illinois). Both for the cells and
for the solid tumours receptor concentration was expressed in
fmol mg proteins-' (Hawkins et al., 1987).
Extraction ofribonucleic acid andnorthern blotting
From frozen tumour, the total ribonucleic acid (RNA) was
extracted using a modification of the method of Auffrey and
Rougeon (1980). A known weight of frozen tumour was
pulverised using a Mikrodismembrator II (Braun, FR Ger-
many) and the resulting powder was finely disrupted using a
plastic pipette in the presence of 2 ml per 100 mg tissue of3M lithium chloride/6 M urea and left at 4°C overnight. Alterna-
tively, cells cultured in vitro were washed in PBS and then
disrupted in 3M lithium chloride/6M urea with a plastic
pipette. The DNA was sheared using a Soniprep 150 ultra-
sonic disintegrator (MSE Scientific Instruments, Crawley,
UK) with an ice jacket. The RNA was recovered by cent-
rifugation at 12,000 r.p.m. and the pellet was taken up in
6 ml 10mmol Tris buffer pH 7.0, 0.1% sodium dodecyl sul-
phate (SDS), 300jig proteinase K (Boehringer Mannheim,
FR Germany) were added and the tube incubated at 37°C for
20min. Protein was extracted using phenol equilibrated with
0.1 M Tris at pH 7 and 24:1 chloroform:isoamylalcohol. Fol- lowing ethanol precipitation of the aqueous phase at -20°C, the RNA was recovered by centrifugation and dissolved in
diethyl pyrocarbonate (DEPC, Sigma, USA) treated, auto-
claved, distilled water and stored in aliquots at -700C. The
quantity and purity of the RNA was assessed spectro- photometrically at 260 nm and 240 nm. Throughout the
RNA extraction procedures, sterile disposable plastic ware
was used where possible; all solutions were made up with
autoclaved DEPC-treated water, using baked glassware and
gloves were worn to minimise exogenous ribonuclease con-
tamination (Maniatis et al., 1982). Twenty micrograms of total RNA was denatured with formamide and formaldehyde at 55°C for 20min; 2gsl loading buffer (50% glycerol, 1 mM EDTA, 0.4% bromo- phenol blue, 0.4% xylene cyanol) and 1 il of 10 ggl-' ethidium bromide were added to each sample. The denatured
specimens were loaded on to a 1.1% agarose gel containing 0.66M formaldehyde, submerged beneath MOPS buffer
(0.2 M morpholinopropanesulphonic acid pH 7.0, 50 mM sodium acetate pH 7.0, 5 mM EDTA) and the RNA species
were separated electrophoretically (modified from Fourney et
al., 1988).
The gel was washed in two changes of 10 x standard saline
citrate (1 x SSC contains 150mM sodium chloride, 15 mM sodium citrate, 1 mM EDTA, pH 7.4), photographed under a
UV transilluminator and the RNA was transferred to a
nylon filter (hybond-N, Amersham, UK) by hydrostatic action using lO x SSC over 8 h (Southern, 1975). The
hybond was rinsed in 2 x SSC, air-dried and the RNA was
covalently fixed to the membrane using a UV transil-
luminator. The hybond and the remaining gel were photo- graphed to check for adequate transfer of the RNA.
Probe hybridisation
Filters were prehybridised in 7% SDS, 0.5 M disodium hy- drogen phosphate pH 7.2 and 1 mM EDTA pH 7.0 (modified from Church & Gilbert, 1984) for 30min at 650C. To this
was added 32P cytidine triphosphate (CTP)-labelled cDNA
probes labelled to 1 x I0' c.p.m. ml-' using the randomprime DNA labelling system (Boehringer Mannheim, FR Ger-
many). 32P-CTP incorporated probe was separated from
unincorporated radionucleotide using a Sephadex column
(Nick column, Pharmacia, UK) and denatured before addi-
tion to the hybridisation solution.
cDNA probe inserts digested from their respective plas- mids were used to detect messenger RNA (mRNA) species for three oncogenes (erbB-2; p53; c-myc) three growth factors
or their receptors (epidermal growth factor receptor; trans-
forming growth factor-beta; transforming growth factor-
alpha) and two hormone-related genes (OR3, pS2). For c-erbB-2, the KpnI-XbaI fragment of lamda 107 was
used (Semba et al., 1985); for p53, the 2.1 kb php53Bam cDNA (Zakut-Houri et al., 1985); and for c-myc, pSV-c-myc- 1 for exons 2 and 3 (Land et al., 1983). Epidermal growth factor receptor (EGFR) was detected with the 3.9 kb pHER- A64-1 probe (Ullrich et al., 1984), transforming growth factor-alpha (TGF-alpha) with a 1.05 kb insert from Sp64- BCI (Derynck et al., 1984) and transforming growth factor
beta with the 1.3 kb insert from Sp65-Cl7N (Derynck et al., 1985). The two hormone-related probes were the 1.6 kb OR3
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0.56 kb cDNA for oestrogen-regulated mRNA (Masiakowski
et al., 1982). As a standard probe, the Pst 1 insert cDNA of
plasmid 91, detecting mouse alpha-actin mRNA specific
sequences (Minty et al., 1981), was used to quantify
accurately each total RNA sample loaded. It is of particular
relevance in this oestrogen-sensitive model that transcription
of actin mRNA in MCF-7 cells is not affected by oestrogen
(Saceda et al., 1988).
Following hybridisation for 24 hours, filters were washed
to remove non-specifically attached probe in two changes of
0.1% SDS 10mmol disodium hydrogen phosphate wash
buffer at 65°C with agitation. Filters were blotted dry, wrap-
ped in cling film and exposed to preflashed Kodak XAR film
at - 70°C for up to 14 days. The extent of hybridisation of
radiolabelled probe to the mRNA species was determined
from densitometry using a laser densitometer constructed by
the Medical Research Council Human Genetics Unit and
expressed with respect to hybridisation to the actin probe.
The size of mRNA species was calculated from the position
of ribosomal RNA markers. Filters were reprobed up to six
times with different cDNA probes; before reprobing, filters
were stripped of residual probe by washing at 80°C for
60 min in 0.1% SDS and the filter was checked by
autoradiography.
Results
One hundred and forty-five CBA strain mice were injected
with MCF-7 cells in this study (Table I). Of the 145 mice
injected, 69 received both cultured MCF-7 cells and oest-
radiol benzoate. Twelve of these 69 mice died before 90 days
leaving 57 for analysis, 30 ofwhich (53%) grew a tumour. Of
36 mice into which tumour was transplanted, four died
prematurely and 23/32 (72%) of the remaining mice grew
tumours. The recultured cells grew as xenografts in 16 of the
18 mice injected which survived (89%). The take rate of
transplanted tumour material was significantly higher than
that of primary inocula (P = 0.04 by Fisher's exact test) and
was higher still for tumour cells that had been recultured in
vitro and then inoculated into fresh mice (P = 0.004 by
Fisher's exact test).
Tumours did not grow without oestrogen supplementation.
The 50,g oestradiol benzoate in arachis oil or the arachis oil
alone were well tolerated by the CBA mice and the oestrogen
delivered in this form promoted tumour growth. The use of
conventional pellets of 1.25 mg or 0.5 mg oestradiol resulted
in 20/20 deaths within 10 days. No consistent cause for these
deaths was evident at post mortem.
Histopathology
Each MCF-7 tumour was firm, pale, solid and well circum-
scribed, not showing overt local invasion or ulceration of the
overlying skin. All the tumours were examined histologically
and were compatible with an origin from breast, although
they did not show marked adenocarcinomatous different-
iaton. There were no areas of necrosis in the smaller
Table I ThefateofMCF-7 cellsinoculated intoimmunocompromised
mice
Number Number oflive mice
MCF-7 Oestrogen ofCBA bearing without
inoculum supplement mice tumours tumours Deaths
Cells Nil 20 Nil 20 Nil
Cells 50gg oestradiol 69 30 (53%) 27 12
benzoate
Transplant 50fig oestradiol 36 23 (72%) 9 4
xenograft benzoate
Recultured 50gg oestradiol 20 16 (89%) 2 2
xenograft benzoate
cells
tumours, although the larger tumours did have evidence of
central necrosis. No marked lymphocyte infiltration was
noted.
Microscopic and macroscopic examination of mice which
died and mice which were killed to obtain tumour showed
evidence of metastasis in only one animal. In that instance,
tumour cells were evident at the site of MCF-7 cell inocula-
tion, as peritoneal seedlings and microscopically in the
visceral pleura of the lung. No pathological evidence of
oestrogen toxicity was found at post mortem in any animal
although there was some hair loss at the site of the oestradiol
injection.
Serum oestradiol concentration
Oestradiol was not detectable in the serum from thymec-
tomised and irradiated mice prior to injection. After injection
with 50gg oestradiol benzoate (Figure 1), a sharp rise to a
mean 7,492 pmol 1'- (s.d. 3,374 pmol 1') oestradiol occurred
by 24h, declining exponentially to undetectable levels (less
than 53 pmol 1-') 2 weeks after the injection.
Tumour growth
The tumours became palpable during the first 3 weeks fol-
lowing 17 13-oestradiol injection and following the second and
third injections of oestrogen, the tumour was observed to
grow in size, but not in a uniform fashion (Figure 1). In
particular, during the first 14 days after injection, the tumour
increased rapidly in size, then from day 14 to 21 slowed
down or became static. By 3-6 weeks, all tumours were large
enough for the studies described.
Cellular DNA synthesis andmitoses
Increased thymidine uptake was noted by 18 h following the
oestrogen injection (Figure 2) and, in parallel with the
percentage of S-phase cells, reached a maximum 24 h follow-
ing oestrogen injection, declining thereafter.
The number of mitoses per x400 field (Figure 2) showed
an increase, compared to the baseline value of 3 per x400
field, to 24 per x400 field demonstrable 24 h following
oestrogen stimulation of the tumour. The level fell to 5
mitoses per x400 field 10 days later. The number of mitoses
showed parallel changes to the biochemical indices of cellular
DNA synthesis.
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Figure I Serum oestradiol and tumour volume in a mouse
xenograft model. Serum oestradiol (mean ± standard deviation)
in thymectomised and irradiated mice for 2-4 mice at each time
point following subcutaneous injection of 50tg 17 P oestradiol
benzoate. From undetectable levels (<53 pmol 1 ') prior to injec-
tion of oestradiol there is a rapid rise to a peak of 7,492pmol-'
followed by a decline in serum oestradiol to undetectable levels
by the third week post-injection (solid dots). Tumour volume
(calculated from pi/12 x mean diameter3) for a cohort of 12 mice
(mean volume ± standard deviation) measured during weeks 3 to
6 following injection of the MCF-7 cells. Only four time points
are shown for clarity (open dots). There is a rise in tumour
volume for the 2 weeks following injection of oestrogen, with
little change in tumour volume once serum oestradiol becomes
undetectable.GENE EXPRESSION IN MCF-7 BREAST CANCER 81
~i50 25
40- 00
c 15 0 15 5 I
2'0 20 10 1 ° (- 15t
1° °L0 °o n 5- R Q 7 a /
U Z L'4 Jb 4d
6 18 30 42
¶ 50 pg Oestradiol Hours
/Z Y0' 21
Days
Four mRNA species for p53 (three at 2.8 kb, one at 1.8 kb)
were identified in the original cell line but only a single
mRNA for p53 was found in tumours or in re-cultured cells.
Similarly, three mRNA species were detected with the pS2
probe in the original cell line but only the single 0.6 kb
mRNA in the tumours. Other cDNA probes such as those
for TGF-beta and c-myc detected only a single mRNA
(2.5 kb in each case) present in both the cell line and xeno-
grafts. There were no differences in any mRNA species
detected between xenografts, transplanted tumours and
tumour cells recultured for periods of up to 56 days.
Figure 2 Three indices of cellular proliferation in xenografts of
MCF-7 cells in mice following administration of oestradiol. Cell
proliferation measured by 3H-dTr uptake (solid dots), percentage
of cells in S phase (open dots) and mitoses per x 400 field (solid
squares) showing mean value of four tumours for each time
point. The same tumours were used for all three indexes of cell
proliferation. Between 12 and 24 h following injection of 17 p
oestradiol benzoate, MCF-7 cells are stimulated to divide, DNA
synthesis returning to prestimulation levels by 48 h and mitoses
declining within days.
Oestrogen receptors
MCF-7 cells in vitro, tumour material taken immediately
before oestradiol injection and cells cultured from xenografts
had a mean 120 fmol (range 110-135 fmol) oestrogen recep-
tors per mg protein. There was a rise to 240 fmol mg-'
protein at 30 h, but at 7, 14 and 21 days following injection,
the level had returned to between 120 and 150 fmol mg'
protein.
Tumour levels ofmRNA
Presence ofmRNA species Messenger RNA was detected in
MCF-7 cells by seven of the nine probes (Figure 3). No
mRNA for EGFR or TGF-alpha was detected in the MCF-7
cells or xenografts, although both mRNA species were
detected in other breast cancer cell lines (MDA-MB-231 and
T47-D). While some mRNA species (c-erbB-2 and OR3)
detected in the MCF-7 cell line were not seen in the xeno-
graft material, no mRNA species was detected in the
tumours which was not present in the original cell line
(Figure 3). The mRNA for c-erbB-2 was detected at 3.0 kb
and 1.8 kb in the original cell line but not in the xenografts.
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Figure 3 Gene expression in MCF-7 cells in vitro and in vivo
(xenografts). Representative autoradiographs of MCF-7 cells,
MCF-7 xenografts and MCF-7 cells re-cultured from the xenog-
rafts after probing with cDNA probes for c-erbB-2, p53, pS2,
c-myc and TGF-beta (details in text). In each case the actin-
probed control for each lane is shown. Two c-erbB-2 species are
evident in the cell line but are not seen in the xenografts. Four
p53 mRNA species are demonstrated in the cell line but only one
in the xenografts and re-cultured cells. Similarly, three species
detected with the pS2 probe are seen in the cell line but only one
species in the xenografts and cells cultured from those xenografts.
The c-myc and TGF-beta probes detect identical species in both
the MCF-7 cell line and the xenograft tumours.
Changes in gene expression after oestrogen stimulation (Figure
4). Densitometry permitted detection of changes in the
levels of mRNA for c-myc, p53, TGF-beta and pS2 with
respect to alpha-actin mRNA, following stimulation of the
xenograft by oestrogen. The mRNAs for c-myc and p53 both
increased then fell back towards the unstimulated level within
the first 24 h while that for TGF-beta was rapidly sup-
pressed, rising only as the oestrogen stimulus declined after 1
week. pS2 expression showed a biphasic response with an
initial increase to 24 h, then suppression for 12 h, a less
substantial increase by 48 h and finally a decline as the
expression of TGF-beta increased.
Discussion
General characteristics
We have established the MCF-7 breast cancer cell line as
xenografts in CBA mice immunocompromised by thymec-
tomy and whole body irradiation. Tissue from these tumours
can be transplanted to similar mice, and cells cultured from
the xenografts can be re-implanted to grow tumours. This
model therefore yields a large renewable supply of tumour
material passaged in vivo and permits the study of tumours
during hormonal manipulation. These MCF-7 tumours were
clearly adenocarcinomata, with necrosis in only the larger
tumours as in nude mice (Osborne, 1988) and metastasis, as
previously noted, a rare event (Busuttil et al., 1986).
As in nude mice, oestrogen supplementation is a pre-
requisite for MCF-7 tumour growth (Shafie & Grantham,
1981; Osborne et al., 1985; Gottardis et al., 1988). The
absence ofdetectable serum oestrogen in female mice prior to
injection confirmed that the mice had been 'oophorectomised'
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Figure 4 Changes in mRNA following oestrogenic stimulation
of MCF-7 xenografts. Host animals were injected with 17p oest-
radiol benzoate at time 0. The changes shown are for c-myc, p53,
pS2 and TGF-beta mRNA species in xenografts, as detected by
densitometry of autoradiographs, with respect to that for actin as
a control. The percentage at each time point is the mean of six
tumours. mRNA expression for the same four species is shown
for the original MCF-7 cells and cells recultured from xenograft
tumours. Levels of c-myc (open squares) and p53 (solid dots)
mRNA reach a peak within 12 h and decline to prestimulation
levels by the second week. pS2 mRNA (solid squares) shows a
biphasic response, with a peak at 12 h, apparent suppression of
this peak to coincide with the peak serum oestradiol at 24 h and
then a further substantial rise and then gentle decline to pres-
timulation values by the second week. In contrast to the other
three species, TGF-beta is slightly suppressed in the first 24 h and
peaks at day 7, returning gradually to prestimulation levels by
day 21 (open dots).82 A.M. THOMPSON et al.
by the irradiation. The serum oestrogen profile following a
single subcutaneous injection of oestradiol benzoate in
arachis oil (Figure 1) gave very high and possibly even
inhibitory serum levels of oestradiol between 12 and 36 h.
From day 2 to day 8, levels of oestradiol were within the
physiological range for non-pregnant premenopausal women
(110-1,630 pmol 1', data from Baxter Health Care, New-
bury, UK) and they remained sufficient to sustain oestrogen-
dependent tumour growth for 21 days. Serum oestradiol
levels in surgically oophorectomised nude mice which have
received the implantable pellet also fall within the same range
(Shafie & Grantham, 1981; Blumenthal et al., 1988). We have
no explanation for the intolerance of our experimental mice
to the implantable pellet, although the findings reported here
confirm our previous experience with this strain (M.E.F. and
C.M.S., unpublished data).
DNA synthesis and mitotic activity of the tumour cells was
evident in respone to oestradiol (Figure 2). The increase in
mitoses from a mean of 3 per x400 field to 24 per field is in
keeping with observations in nude mice (5 and 25 mitoses per
x 400 field respectively; Osborne et al., 1985). Similarly, des-
pite possible influences on the thymidine pool by oestradiol,
thymidine uptake and the % S phase cells confirmed the
histological observation that, following oestrogen administra-
tion, there was an increase in cell proliferation, which
preceded the increase in tumour volume.
The slight rise in oestrogen receptor protein following
oestrogen stimulation of the tumour, from 120 fmol mg-'
protein to 240 fmol mg-' protein, and its subsequent return
to basal level is consistent with the view that oestrogen can
stimulate the synthesis of its own receptor.
mRNA species
The mRNA species detected, particularly in the MCF-7 cells
in vitro, merit comparison with published data. Using the
oncogene probes to study the RNA from MCF-7 grown in
vitro, two distinct mRNAs of 1.8 and 3.0 kb were identified
hybridising to the c-erbB-2 probe, both smaller than the
single 4.8 kb mRNA species previously described (Semba et
al., 1985) and identified in breast tumours and normal
human tissues (data not shown). An amplified and rear-
ranged epidermal growth factor receptor in epidermoid car-
cinoma cells generating a truncated 2.8 kb mRNA that
encoded only the extracellular EGF binding domain has been
reported previously (Ullrich et al., 1984). Just as the c-erbB-2
gene may be rearranged in the MCF-7 cells studied, trun-
cated transcription may occur. Certainly, alternative trans-
cription mechanisms have been proposed for the c-erbB-2
gene (Tal et al., 1987).
It is well recognised that a single gene can give rise to a
variety of mRNA transcripts: the three p53 mRNA species of
circa 2.8 kb similar to the 2.8 kb mRNA in human breast
tumours (Thompson et al., 1990) may result from such
mechanisms as different transcription initiation sites,
differential splicing or other post-transcriptional modific-
ation. Certainly, the mean size observed corresponds well to
published data for the human p53 mRNA (Zakut-Houri et
al., 1985; Harlow et al., 1985), and the additional 1.8 kb
mRNA identified is probably still large enough to encode a
53 kDa protein. The c-myc mRNA of 2.5 kb corresponds to
that previously reported in MCF-7 cells (Zajchowski et al.,
1988). The 2.5 kb mRNA for TGF-beta was of the expected
size (Derynck et al., 1985; Travers et al., 1988).
Although mRNA for the epidermal growth factor receptor,
and the mRNA for TGF-alpha, which acts upon it, have
been reported in MCF-7 cells (Dickson et al., 1986, Arteaga
et al., 1988), none was evident in the MCF-7 cell line tested
here, suggesting that the MCF-7 cells in use in our
laboratory may be variants of those used in some previous
studies.
OR3, the probe for oestrogen receptor mRNA detected
two messages of 3.0 and 1.7 kb, but no 6.2 kb mRNA. As in
this study, Henry et al. (1988) were unable to demonstrate
oestrogen receptor mRNA in the MCF-7 cell line using the
OR3 cDNA clone, but demonstrated hybridisation to a
6.2 kb mRNA using their radionucleotide labelled RNA
probe. While mRNA of 6.2 kb (Walter et al., 1985), 4.2 kb
(Parl et al., 1987) and 3.7 kb (Barrett-Lee et al., 1987) has
been reported in human tumour tissue and in the MCF-7 cell
line, the species identified here do not correspond to any of
these. It is therefore possible that the probe used did not
detect the oestrogen receptor mRNA (perhaps due to the
experimental conditions) or alternatively that the MCF-7
cells used in this study produce oestrogen receptor mRNA
smaller in size than that previously identified. However, the
translated oestrogen receptor protein was certainly present
when assayed by enzyme immunoassay.
The pS2 probe appears to cross-hybridise to the same 3 kb
and 1.7 kb mRNA as the OR3 probe but hybridises most
strongly to a small mRNA of about 600 base pairs (Figure
3), corresponding to the oestrogen induced mRNA of
Masiakowski et al. (1982). The biphasic change in pS2 sug-
gests that the role of pS2 as a marker for oestrogen action
may not be as simple as originally proposed.
mRNA differences in vitro and in vivo
The original MCF-7 cells grown in vitro expressed several
mRNA species not evident in the xenografts or in cells of
these xenografts recultured for some time in vitro. These
findings may indicate in vivo selection for a subpopulation of
cells within the MCF7 culture.
The MCF-7 cells re-cultured from xenografts had an iden-
tical pattern of gene expression to the xenografts and did
not, over an 8-week period, revert to the original MCF-7 cell
line pattern. Serious consideration was given to the pos-
sibility that these findings could be due to a contaminant in
the original cell line (such as mycoplasma) expressing the
gene concerned or to contamination (perhaps by a plasmid)
at some point in the RNA extraction or electrophoresis. Both
these explanations are unlikely since tests on the MCF-7
culture (Barile, 1973) were persistently negative for myco-
plasma, and no evidence of plasmid contamination was
found in these or any other northern-blot RNA studies.
Moreover, a range of different plasmids was used as vectors
for the cDNA probes.
mRNA changesfollowing oestrogen stimulation
Oestrogen-induced stimulation of c-myc expression,
previously noted in breast cancer cells in vitro (Dubik et al.,
1987), was confirmed. The expression of c-myc and p53 at
elevated levels in the xenograft tumours in response to oest-
rogen suggest that in vivo the expression of these two nuclear
genes may be involved in cell cycling (Kelly & Seibenlist,
1985; Lamb & Crawford, 1986). In vitro work (Brown et al.,
1984) identified an increase of pS2 mRNA in response to
oestrogen which was attributed to increased transcription.
The biphasic response ofpS2 mRNA noted in this study may
reflect initial oestrogenic stimulus then, as the oestrogen
achieves a peak, inhibition of pS2 transcription, with subse-
quent pS2 stimulation as the serum oestrogen returns to
more physiological levels.
Similarly, a decrease in TGF-beta transcription has been
noted in vitro in response to oestrogen treatment of MCF-7
cells (Dickson et al., 1986). Both these effects were noted in
vivo in response to oestrogen. In the present xenograft
system, TGF-beta transcription increased as the mitogenic
stimulus of oestrogen declined, compatible with the anti-
proliferative effects noted on oestrogen receptor-positive
breast cancer cell lines in vitro (Kerr et al., 1989).
Clinicalimplications
Gene expression in the breast cancer cells, as detected by
mRNA analysis, obviously changes when cells cultured in
vitro grow as tumours in vivo. The physiological and clinical
significance of in vitro observations have on occasion been
controversial and may be difficult to interpret due to lack ofGENE EXPRESSION IN MCF-7 BREAST CANCER 83
host-related determinants that affect tumour behaviour in
vivo (Shafie & Grantham, 1981). Certainly, different effects
on cell kinetics have been observed using MCF-7 cells in vitro
compared to nude mouse xenografts (Brunner et al., 1989).
The model we describe here provides information com-
plementary to that obtained from in vitro work and from
clinical studies, particularly in examining host-tumour cell
interactions and in determining the role of gene expression in
oestrogen-dependent breast tumour growth.
The MCF-7 xenografts in thymectomised and irradiated
CBA strain mice therefore present a useful model for examin-
ing the in vivo behaviour of oestrogen-dependent breast
cancer and has considerable potential for the study of the
actions of therapeutic agents in vivo.
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